This company will revolutionize psychiatric therapy and provide life-changing solutions to big problems in mental health and neurology.
As an investor and someone who has tackled mental health obstacles, I am very excited to tell you more about Bright Minds Biosciences. This company is a new generation of brain health. They will be IPO’ing on the Toronto Stock Exchange in less than two weeks under ticker symbol $DRUG.
Bright Minds has a wide portfolio of medications and drugs they work on and are released into the market. They are the only company that has patents on serotonergic selective agents — one of the leading neuropsychiatry aspects.
About Bright Minds Biosciences
Bright Minds creates revolutionary compounds for people who need healing. They are one of the few biotechnical companies that use targeted therapy to reach more defined patient populations rather compared to
The company was founded on November 1st, 2017, in Ontario, Canada, and held its headquarters in Great Lakes.
Bright Minds Biosciences became possible thanks to CEO Ian McDonald and Co-Founder, Dr. Alan Kozikowski Ph.D. They have an incredible team including Chief Medical Officer Dr. Revati Shreeniwas MD and Vice President of Discovery, Dr. Gideon Shapir Ph.D.
This team of top scientists has an average of 25+ years of experience in drug development, and they are tapping into the biotechnology industry with a broad portfolio of new chemical entities (NCEs).
They are heavily focused on psychedelic compounds and have a captivating portfolio—an emphasis on diversity.
The Only Company With Patents on Serotonergic Selective Agents
A Serotonergic selective agent is a type of drug that induces serotonin release into the neuronal synaptic cleft. Serotonin plays an important role in maintaining normal brain function. Imbalances often lead to mental health and neurological ailments.
Bright Minds’ neuroscientists are driven to create the next generation of serotonin drugs that will target specific conditions leading to a dramatic reduction in side effects and improved therapeutic action transforming patient lives. Their compounds allow specific serotonin activity back in line with normal levels.
According to Deutsche Bank, The US Patent and Trademark Office defines a patent as “the right to exclude others from making, using, offering for sale, or selling” the invention in the United States, or importing the invention into the United States for a limited time (currently 20 years in most cases).
First-generation psychedelics like psilocybin provide personalized specific drugs to target the serotonin. The compounds Bright Minds develops works for the brain improving safety and efficacy.
How Bright Minds Separates Themselves From The Competition
Psychadelic medicine is going to be a movement that changes the world. Not many biotechnology companies are tapping into the psychedelic and the intellectual market, if any. That’s what makes Bright Minds so unique. They’re ahead of the curve in an evolving market that’s waiting to blow up.
Their patented, lead product candidates feature next-generation characteristics, reducing unwanted side effects, and maximizing therapeutic attributes. Not every company is like Bright Minds, however.
2 Problems differing companies’ drugs have are cardiotoxicity and the scope of use:
- Cardiac toxicity is damage to the heart by harmful chemicals. As part of your treatment, you may be given toxins (drugs) to kill cancer cells. A side effect is that the normal cells in and around your heart can also be killed (NCCN).
- Scope of use refers to the fact that a high prevalence of prescription drug misuse varies by age, gender, and other factors but likely includes ease of access.
Bright Minds Will Tackle Opiate Addiction
My research on Bright Minds illuminates the point that their tools to solve brain health will prevent opiate prescriptions and help society lessen opiate addiction in the future.
Some drug interactions involving opioids can increase intrasynaptic levels of docserotonin (Pub Med).
It’s outstanding to see that Bright Minds can do a service to society and has goals to reduce the usage of opiates. Opiate usage accounts for 2 out of every 3 overdose deaths in 2018 (U.S. Department of Health and Human Services).
Bright Minds is The Future
Bright Minds is one of a kind and is making is gaining great momentum in the biotechnology industry. They have an addressable market in the U.S. of at least 3 million patients and even more worldwide.
Their Psilobycin treatment reduces the “trip” time and gives emits life-changing benefits of positivity and a sense of unity from a therapist.
Once the market becomes more familiar with Bright Minds, it will have a rapid inflow of investors and patients who use their products.
As someone who isn’t typically intrigued by biotechnology, the life-changing benefits of Bright Minds has my attention. Since they can provide a solution for people who battle mental health ailments like me, I can confidently say the future looks bright.